Routine prophylaxis

Calendar icon
78% of patients had zero bleeds
while taking twice-weekly prophylaxis

On-demand treatment

Blood droplet and hand icon
98% of bleeding episodes were controlled with one or two infusions

Perioperative management

Factor X Deficiency specialist icon
100% of investigators rated COAGADEX as “excellent” for pre- and post-operative use in surgeries

COAGADEX Prevented Bleeding in Major and Minor Surgeries

In a pooled analysis of two clinical trials and a post-marketing study, 10 surgeries in 8 patients with hereditary factor X deficiency (HFXD) were evaluated to establish the efficacy and safety of perioperative use*1,2

100%
100% of investigators rated COAGADEX as “excellent” for pre- and post-operative use in major and minor surgeries
Investigator rating of “excellent” meant hemostatic parameters were similar to those in patients without a bleeding disorder—
No post-operative bleeding
No requirement of blood transfusions
Blood loss no more than “as expected”

Major Procedures
(n=5 subjects)

Total Hysterectomy and Ovarian Cystostomy
(1 subject)
Removal of Pectus Bar and Excision of Scrotal Lesion
(1 subject)
Hernia Repair and Small Bowel Resection
(1 subject)
Total Knee
Replacement
(Both knees in 1 subject)
Coronary Artery Bypass Graft and 6 Tooth Extractions
(in 1 subject)

Minor Procedures
(n=3 subjects)

Tooth Extraction
(1 extraction in 2 subjects)
Tooth Extraction
(2 extractions in 1 subject)

Safety Findings

  • No adverse events related to treatment
  • No thrombotic events
  • All inhibitor results were negative, and no viral seroconversions were detected
Review
the Study Escobar M, et al.
Haemophilia. 2016. Study in surgical patients
*All patients were <10 IU/dL at baseline.
References: 1. Escobar M, et al. Haemophilia. 2016;22:713-720. 2. Escobar MA, Kavakli K. Haemophilia. 2024;30:59-67.
See Available Resources for You and Your Patients
Replace exactly what's missing

Indications and Usage for COAGADEX

COAGADEX, a plasma-derived blood coagulation factor X concentrate, is indicated in adults and children with hereditary factor X deficiency for:

  • Routine prophylaxis to reduce the frequency of bleeding episodes
  • On-demand treatment and control of bleeding episodes
  • Perioperative management of bleeding in patients with mild, moderate and severe hereditary factor X deficiency

Contraindication for COAGADEX

COAGADEX is contraindicated in patients who have had life-threatening hypersensitivity reactions to COAGADEX.

Important Safety Information for COAGADEX

Allergic type hypersensitivity reactions, including anaphylaxis, are possible with COAGADEX. If symptoms occur, patients should discontinue use of the product immediately, contact their physician, and administer appropriate treatment.

The formation of neutralizing antibodies (inhibitors) to factor X is a possible complication in the management of individuals with factor X deficiency. Carefully monitor patients taking COAGADEX for the development of inhibitors by appropriate clinical observations and laboratory tests.

COAGADEX is made from human plasma and may contain infectious agents, e.g. viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. No cases of transmission of viral diseases, vCJD or CJD, have been associated with the use of COAGADEX.

In clinical studies, the most common adverse reactions (frequency ≥5% of subjects) with COAGADEX were infusion site erythema, infusion site pain, fatigue and back pain.

Please see complete Prescribing Information for COAGADEX.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit https://www.fda.gov/medwatch, or call 1-800-FDA-1088.
You may also call Kedrion at 1-866-398-0825 or email US_Medicalinfo@kedrion.com.

IMPORTANT SAFETY INFORMATION